Sinopharm’s Booster Shot Offers Less Protection Against Omicron
This article is for subscribers only.
Sinopharm’s Covid-19 booster shot generated “significantly lower” levels of antibodies against the omicron variant, in a study offering further clues on how one of the world’s most widely used vaccines stands up against the new strain.
A study of 292 healthcare workers given a booster 8 to 9 months after their second dose found that omicron caused a 20.1-fold reduction in neutralising antibodies, compared to the performance against the original Wuhan strain.